Management of Abnormal Uterine Bleeding with Bhumyamalaki Churna and Madhuka Ghrita Basti- A Comparative Clinical Study

A Randomized Comparative Clinical Study of Bhumyamalaki Churna and Madhuka Ghrita Matra Basti in the Management of Asrigdara vis-Ã -vis to Abnormal Uterine Bleeding.

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/06/019603

Enrollment

Registered

2019-06-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: Madhuka Ghrita Matra Basti: Madhuka, Ghrita- Matra Basti 60ml Just after food 7 days each in 2 consecutive cycle from seven day before due date of menstrual cycle. Control Intervention1

Eligibility

Inclusion criteria

Inclusion criteria: Patients complaining of Abnormal uterine bleeding having any two of the following symptoms Excessive bleeding during menstruation (menstrual blood loss > 80 ml in 1-7 days) having Pictorial blood loss assessment chart (PBLAC) score more than 100 points for 2 consecutive cycles Prolonged menstrual bleeding (With the duration of bleeding >7 days) Inter menstrual bleeding Frequent menstrual cycle (interval

Exclusion criteria

Exclusion criteria: Patients having bleeding due to abortion. Patients having coagulation disorders. Patients having bleeding after menopause. Any type of malignancy. Puberty menorrhagia. Patients having STDs. Patients having any systemic diseases. Hb% Women using IUCD or Pill.

Design outcomes

Primary

Measure	Time frame
I Changes in the clinical features of AUB ie changes in the amount of uterine bleeding evaluated by PBLAC (Pictorial Blood Loss Assessment Chart). II. Changes in the duration of bleeding. III. Attainment of normal interval of cycles Timepoint: 2 Months	—

Secondary

Measure	Time frame
1. To Conceptual study (Aetiopathogenesis) of Asrigdara. 2. To evaluate the therapeutic efficacy and safety of Bhumyamalaki Churna in Asrigdara. 3. To evaluate the therapeutic efficacy and safety of Madhuka Ghrita Matra Basti in Asrigdara. 4. Comparative efficacy of Bhumyamalaki Churna and Madhuka Ghrita Matra Basti in Asrigdara. Timepoint: 2 Months	—

Countries

India

Contacts

Public Contactsanju rao

National Institute of Ayurveda Jaipur

pushpalathania@gmail.com09413206790

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026